Statins, particularly simvastatin, have also been tested as adjuvants to conventional regimens such as XELOX, where they did not increase toxicity, but showed comparable efficacy in patients with metastatic CRC as first-line chemotherapy [78], Cetuximab, where it was not able to restore sensitivity in CRC patients harbouring a somatic KRAS mutation [79], and FOLFIRI where, indeed, it was able to prolong time to progression in CRC patients [80]. This evidence concerns the gene KRAS and colorectal carcinoma.